The Global Autism Disorder and Treatment Market is currently dominated by various few players. Bristol-Myers Squibb and Otsuka Holdings Co., Ltd. are one of those by holding a strong share in the market. Bristol-Myers Squibb is a U.S. based pharmaceutical company and Otsuka Holdings Co., Ltd. has head office in Japan. Both the companies in collaboration introduced ABILIFY® (aripiprazole) drug for the treatment of conditions associated with autistic disorder. The drug had received approval November 20, 2009. Currently, there are only two FDA approved drugs for autistic disorder in the market i.e., Abilify (aripiprazole) and risperidone. Risperidone is a second-generation antipsychotic drug, received approval from FDA to treat autistic disorders in 2006. Risperidone was introduced by Janssen Pharmaceuticals, Inc. Janssen Pharmaceuticals operates as a subsidiary of Johnson & Johnson Services, Inc. by manufacturing prescription pharmaceutical products. Risperidone, despite of its benefits, has its known side effects that clinicians have to balance for a subset of autistic people.
Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1605 .
Regional Analysis: Autism Disorder and Treatment Market
The Autism Disorder and Treatment Market is expected to be concentrated across the eight major countries such as US, Canada, France, UK, Germany, Spain, Italy, and, Japan. Regional market analysis reflects the dominance of developed world on the Autism disorder treatment market. North America leads the world and is closely followed by Europe. The Asian continent is led by Japan. A close observation will reflect the fact that increasing screening is the likely cause of increasing Autism cases. This reflects untapped and unmet needs of the developing world. Thus the market will be dominated by developed regions in the years to come and only after advent of a specific drug will the developing region market pick up. Market for non-pharmacological treatment especially in the developing world will be more affected by government policies and rising incomes.
Products in the pipeline
Due to the rising demand, and to meet the untapped and unmet needs various companies are coming up with innovative autism treatment products. For instance, RG7314, by F. Hoffmann-La Roche Ltd, is a potent small molecule antagonist of the V1A vasopressin receptor is under clinical trials to treat Autism spectrum disorders. Various other companies such as, APeT Holding BV, BioCrea GmbH, Coronis Partners Ltd., Curemark LLC, Heptares Therapeutics Limited, Intra-Cellular Therapies Inc., Saniona AB, and others are continuously putting efforts to introduce new effective drugs to treat autism , and related problems. Global key Players : GlaxoSmithKline plc (U.K), pfizer inc. (U.S.), Eli Lilly and Company (U.S.). Allergan (Ireland), Merck & CO Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Consern Pharma Private Limited (India) are some of the prominent players profiled in MRFR Analysis and are at the forefront of competition in the Global Autism Disorder and Treatment Market.
Browse Complete Premium 90 Pages Half Cooked Research Report Enabled with Respective Tables and Figures is Available @ https://www.marketresearchfuture.com/reports/autism-disorder-treatment-market-1605 .
The Major Table of Content for Autism Disorder and Treatment Market:
1 Report Prologue
2 Market Introductions
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
3 Research Methodologies
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/1605 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future,
Office No. 528, Amanora Chambers,
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312
Email: email@example.com .